Prevention of prion disease symptoms in mice with deep PrP lowering
This study demonstrates that a highly potent, C16-conjugated siRNA therapy capable of deeply lowering PrP levels in the brain effectively prevents prion disease symptoms in mice and significantly extends survival even after symptom onset, while also showing efficacy in humanized mice and macaques.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Prion diseases are a rare but devastating group of conditions that attack the brain, causing rapid decline and inevitably leading to death. They are caused by a specific protein, naturally found in our bodies, that occasionally folds into the wrong shape. Once this misfolded protein appears, it acts like a template, forcing other healthy proteins to twist into the same harmful shape. This chain reaction creates clumps that destroy brain tissue. For decades, scientists have known that if you remove the healthy protein entirely, the disease cannot start. However, removing a protein completely is not something medicine can currently do in a living person. The big question has been whether lowering the amount of this protein just enough to slow the disease down is sufficient, or if the key to stopping it entirely lies in reducing it as much as possible.
A new study involving mice suggests that the answer is the latter: to truly stop the disease, you must lower the protein levels drastically. Researchers used a specialized tool, a type of genetic instruction called an siRNA, to target and silence the gene that produces this protein. They delivered this tool directly into the fluid surrounding the brain. In mice that were infected with the disease-causing agents but treated before any symptoms appeared, the treatment lowered the protein levels to just 12 percent of normal. The result was striking. These animals remained completely healthy and showed no signs of illness for more than 500 days, a time frame that covers the vast majority of a mouse's natural life. In contrast, untreated mice typically succumb to the disease in less than half that time. The treatment did not just delay the inevitable; it appeared to halt the progression of the disease entirely in these early-treated animals.
The researchers also tested whether this deep reduction could work against different types of the disease. Prion diseases come in different strains, some of which respond well to modest reductions in protein levels, while others are much harder to stop. The study found that even the stubborn, difficult-to-treat strains were completely prevented from causing symptoms when the protein was lowered to this very low level. This suggests that the difference between strains might not be how fast they replicate, but rather how toxic they are to the brain. When the protein supply is cut off almost entirely, even the most aggressive strains cannot cause harm.
However, the timing of the treatment proved to be critical. When the researchers waited until the mice were already showing clear signs of sickness before starting the treatment, the results were very different. While the treatment still helped the animals live longer, it could not reverse the damage that had already occurred, nor could it stop the disease from eventually taking hold. This indicates that the window for a cure is narrow; the treatment works best as a preventative measure before the brain begins to show signs of distress. The study also looked at whether the treatment could clear the harmful protein clumps that had already formed. While the levels of these clumps dropped significantly, they did not disappear completely, suggesting that the treatment stops the creation of new clumps but does not necessarily sweep away the old ones.
To see if these findings could apply to humans, the team tested a similar version of the drug in monkeys. They found that a single injection into the spinal fluid could lower the protein levels in the brain and spinal fluid of the monkeys for months, demonstrating that the method works in animals much closer to humans. While the study was conducted on mice and monkeys, and the drug used was a research tool rather than a final medicine, the results point toward a new path for treating these diseases. The key takeaway is that the depth of the protein reduction matters more than previously thought. To prevent the disease, the goal must be to lower the protein levels as close to zero as safely possible, rather than just cutting them in half. This approach offers a glimmer of hope that if caught early enough, the progression of these fatal conditions might be stopped entirely.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.